Recursos
COSOPT: Una potente solución - Referencias
  1. Boyle JE, Ghosh K, Gieser DK y cols. Dorzolamide-Timolol Study Group. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1998;105(10):1945-1951. 

  2. Janulevicienë I, Harris A, Kagemann L, y cols. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand. 2004;82:730-737. 

  3. Konstas AG, Papapanos P, Tersis I, y cols. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology. 2003;110:1357-1360.

  4. Martinez A, Gonzalez F, Capeans C, y cols. Dorzolamide effect on ocular blood flow. Invest Ophthalmol Vis Sci. 1999;40(6):1270-1275.

  5. Feldman RM, Stewart RH, Stewart WC, y cols. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed combination ophthalmic solution in open-angle glaucoma. Curr Med Res Opin. 2008;24:2403-2412.

  6. Datos en archivo MSD.

  7. Jaenen N. Boudouin C, Pouliquen P y cols. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341-349.
 
 
PrintImprimir esta página
05-11-CST-2009-LAMT-1322113-W

† Marca registrada de Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc., Whitehouse Station, N.J., E.U.A.

Derechos reservados © 2003 Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc., Whitehouse Station, N.J., E.U.A
Privacy Policy Terms of Use Coyright © 1995-2007 Merck & CO